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Abstract
Protease-Activated Receptor-2 (PAR2) has been implicated through genetic knockout mice with cytokine regulation and
arthritis development. Many studies have associated PAR2 with inflammatory conditions (arthritis, airways inflammation,
IBD) and key events in tumor progression (angiogenesis, metastasis), but they have relied heavily on the use of single
agonists to identify physiological roles for PAR2. However such probes are now known not to be highly selective for PAR2,
and thus precisely what PAR2 does and what mechanisms of downstream regulation are truly affected remain obscure.
Effects of PAR2 activation on gene expression in Human Embryonic Kidney cells (HEK293), a commonly studied cell line in
PAR2 research, were investigated here by comparing 19,000 human genes for intersecting up- or down-regulation by both
trypsin (an endogenous protease that activates PAR2) and a PAR2 activating hexapeptide (2f-LIGRLO-NH2). Among 2,500
human genes regulated similarly by both agonists, there were clear associations between PAR2 activation and cellular
metabolism (1,000 genes), the cell cycle, the MAPK pathway, HDAC and sirtuin enzymes, inflammatory cytokines, and anti-
complement function. PAR-2 activation up-regulated four genes more than 5 fold (DUSP6, WWOX, AREG, SERPINB2) and
down-regulated another six genes more than 3 fold (TXNIP, RARG, ITGB4, CTSD, MSC and TM4SF15). Both PAR2 and PAR1
activation resulted in up-regulated expression of several genes (CD44, FOSL1, TNFRSF12A, RAB3A, COPEB, CORO1C, THBS1,
SDC4) known to be important in cancer. This is the first widespread profiling of specific activation of PAR2 and provides a
valuable platform for better understanding key mechanistic roles of PAR2 in human physiology. Results clearly support the
development of both antagonists and agonists of human PAR2 as potential disease modifying therapeutic agents.
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Introduction
Currently ,900 human G protein-coupled receptors (GPCRs)
are annotated, forming a diverse family of membrane-spanning
cell-surface proteins that may account for .2% of the human
genome [1,2]. Typically GPCRs are single polypeptide chains
containing seven membrane-localized helices connected by three
extracellular and three intracellular loops, with extracellular amino
and intracellular carboxyl termini. Both extracellular and
intracellular domains vary substantially in size, the former having
evolved to selectively recognize many types of GPCR-activating
extracellular ligands, while the latter mediate signal transduction
through coupling to combinations of G proteins resulting in
extensive functional diversity [3]. Protease activated receptors
(PARs) are unusual GPCRs [4] with as yet no known endogenous
extracellular ligands. PARs are however indirectly activated by
proteases which cleave the N-terminus of at least four PAR
isoforms, exposing a new N-terminus that folds back and
intramolecularly self-activates PAR [5]. Short synthetic peptides
corresponding to the new N-terminus can trigger PAR activation,
but only at much higher concentrations than proteases [4]. The
most active reported PAR2 agonist is the hexapeptide 2-furoyl-
LIGRLO-NH2 (EC50,200 nM). PAR2 is activated by mainly
serine proteases (e.g. trypsin, tryptase, cathepsin G) but not
thrombin and may be linked to inflammatory and proliferative
disorders [4].
PAR2 activation has been linked to cancer progression,
especially metastasis and angiogenesis [6,7,8,9], as well as pro-
inflammatory [10,11,12,13,14,15] and anti-inflammatory [16,17]
properties depending on the system, although this is controversial
and not well understood. PAR2 activation reportedly causes blood
vessel relaxation, increased vascular permeability, leukocyte
adhesion [18], and release of pro-inflammatory cytokines (e.g.
IL-1b, IL-6, IL-8, TNF-a) and Intracellular Cell Adhesion
Molecules-1 (ICAM-1) from human blood monocytes [19,20].
PAR2 deficient mice show impaired production of IgE and IL-4
[21], reduced contact sensitivity in a model of allergic inflamma-
tion in the airways [22], and resistance to adjuvant-induced
arthritis [12] or delayed onset of inflammation [23]. PAR2 is
reportedly implicated in the pathogenesis of cardiovascular disease
[24], gastric ulcers [25,26], asthma [15,27], and liver fibrosis
[28,29].
On a cautionary note, many cellular and physiological effects of
PAR2 activation have been implicated solely through the use of
PAR2 peptide agonists (e.g. SLIGKV-NH2, SLIGRL-NH2,2 -
furoyl-LIGRLO-NH2) now known to be non-selective for PAR2
over other targets, even though selective over PAR1. Such agonists
can activate neurokinin-1 receptor and other receptors
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PAR2 activation, reportedly an inhibitor of TNF-a and IL-1b
release [34], has only mM affinity for PAR2 and selectivity for this
one receptor is extremely unlikely. Our understanding of PAR2 in
human physiology and disease is thus still limited by the lack of
truly selective and potent ligands suitable for in vivo studies.
For these reasons we have used a microarray approach, with
two structurally and mechanistically different PAR2 agonists, to
clearly establish effects of PAR2 activation on human gene
expression. We compare intersecting gene expression profiles
following separate PAR2 activation by a peptide (2f-LIGRLO-
NH2) versus a serine protease (trypsin), expecting that genes up- or
down- regulated by both agents might help identify cellular
pathways associated with PAR2 activation. We studied human
embryonic kidney cells HEK293 because of their widespread use
in PAR2 research [4], their presence on kidney epithelial,
mesangial, and infiltrating renal inflammatory cells [35,36,37],
known Ca
2+ release from HEK293 cells treated with trypsin and
PAR2 activating peptides [38,39], and because of possible roles for
PAR2 in inflammation, ion transport, blood flow regulation, cell
growth and repair in the kidney [37]. A limited gene expression
profile has been reported for PAR1 activation by thrombin using
cDNA microarray analysis, with 65 genes induced in HMEC-1
cells [40], enabling some comparison between PAR2 and PAR1
activation on gene expression. Here we show that PAR2 activation
in HEK293 cells impacts widely on metabolic and proliferative cell
cycle pathways, and on some notable mediators of the inflamma-
tory immune response.
Results
Genes regulated by trypsin and peptide agonists
To identify candidate genes that might be differentially
expressed as a result of PAR2 activation in human embryonic
kidney cells (HEK293), cDNA microarray analyses were per-
formed using a human Compugen array of ,19,000 different
human genes. HEK293 cultures were treated with a high dose of
either PAR2 activating peptide (2f-LIGRLO-NH2,1 mM) or
trypsin (50 nM) for 1.5–12 h. Total RNA was then isolated from
treated versus untreated cells at 1.5, 3, 6, 12 h following PAR2
activation. Control and treated cDNA were hybridized to array
chips simultaneously. Raw data was quantified, normalized and
filtered according to criteria above. There were 5,270 genes that
changed significantly (P,0.01) in response to either trypsin or 2f-
LIGRLO-NH2. These genes were categorized into 5 clusters
based on whether upregulated (cluster1) or downregulated (clusters
2 and 3) by both treatments (Figure 1), upregulated by PAR2
activating peptide but downregulated by trypsin (cluster 4), or
downregulated by PAR2 activating peptide but upregulated by
trypsin (cluster 5). About half of these genes were similarly up- or
down- regulated by both treatments (clusters 1–3).
The objective was to focus on identifying an intersecting set of
genes that were either up- or down- regulated significantly by
both methods of PAR2 activation. This approach was taken
because trypsin is highly promiscuous in its effects on cell surface
proteins, and the agonist peptide (2f-LIGRLO-NH2)h a sb e e n
shown to be selective for PAR2 over PAR1 [11] but little
information is available about its selectivity for PAR2 over other
GPCRs or other receptors. Therefore we considered that results
obtained from either treatment alone would not clearly define
specific gene expression profiles that could be unambiguously
attributed to PAR2 activation. However, by comparing genes
regulated in a similar fashion (both up- or both down-) by both
treatments, it seemed likely that the common effects could be
directly attributed to activation of their common receptor PAR2,
since the protease and short peptide are unlikely to share other
mechanisms.
Figure 1. Microarray analysis of PAR2 induced gene expres-
sion. HEK293 cells were treated with either trypsin (50 nM) or 2f-
LIGRLO-NH2 (1 mM). Total RNA was harvested at different time points
after treatment (Trypsin, 6 h; Agonist, 1.5, 3, 6, 12 h). Control and
treated cDNAs were hybridized to the ,19,000 cDNA microchip and
results were quantified, normalized and filtered as outlined in
experimental procedures. (A) Heatmap (red, up-regulated; green,
down-regulated) featuring 5 gene clusters. Three clusters show similar
modulation by PAR2 peptide agonist and trypsin (1, 2, 3). Cluster 1
shows genes up-regulated by PAR2 activation, clusters 2 and 3 show
genes suppressed by PAR2. Clusters 4 and 5 show opposing effects
resulting from PAR2 peptide agonist versus trypsin. (B) Scatter plot of
genes regulated by trypsin and PAR2 agonist peptide after 6 h
treatment. Dots in right hand top quadrant are genes up-regulated
by both trypsin and peptide, those in bottom left hand quadrant are
genes down-regulated by both treatments. Blue lines depict regions
where gene expression increased or decreased by#3 fold.
doi:10.1371/journal.pone.0013809.g001
Gene Regulation by PAR2
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Expression of PAR2 mRNA itself was found to slightly increase
upon treatment with trypsin (1.7 fold) or PAR2-AP (1.2 fold) for up
to 6 h. The effects eventually returned to baseline 12 h after
stimulation, but were significant enough to qualify as evidence that
PAR2 expression was upregulated in response to PAR2 agonists.
A number of genes were upregulated more than 4 fold or
downregulated more than 3 fold in response to both PAR2
agonists. The two most up-regulated genes were dual specificity
protein phosphatase 6 (DUSP6) and WW domain-containing
oxidoreductase (WWOX) with 7.5 fold and 8 fold increases
respectively. Others were AREG, SERPINB2, IL-8, THUMPD1,
and SPRY2. Also there were 6 genes that were 3 fold or more
down-regulated versus normal (e.g. 0.3 fold of control). These
genes are TXNIP, RARG, ITGB4, CTSD, MSC and TM4SF15.
More detailed profiles of these genes are in Table 1 and discussed
ahead.
PAR2 activation and the cell cycle
PAR2 has been linked to cellular proliferation and cancer
biology. Microarray data were therefore checked for these cellular
functions and 136 genes associated with cell cycle regulation were
found to be affected similarly by both trypsin and agonist peptide. A
representative group of 55 such genes are listed in Tables 2 and 3.
This data suggests that PAR2 regulates the cell cycle at the
transcriptional level, modulating the expression of a number of
important genes including crucial regulators of cell cycle
transitions such as the cyclin family (CCNA1, CCNF, CCNYL1)
and cyclin-dependent kinases (CDK5, CDK10). CCNA1 and
CCNYL1 were upregulated 2 and 1.5 fold respectively, and
expression of CCNF, CDK5 and CDK10 were suppressed, up to 2
fold for CDK10. Among other key players in cell cycle progression
that were affected by PAR2 activation were tumor suppressor p53,
cell division cycle members CDC123, CDC20 and CDC25A, and
cell cycle regulators such as PPP2CA and PPP2CB.
Surprisingly, not all genes associated with strong proliferative
responses were up-regulated following PAR2 activation. Instead,
some genes important for cell proliferation were down-regulated,
while others were up-regulated (Figure 2). For example, expression
of cyclin F and ERK1 were down-regulated ,2 fold (,0.5 fold of
control), while cyclin A1 and KRAS were up-regulated ,2 fold.
Similar effects were observed for growth suppressing genes NEK9
(suppressed), p53 (suppressed) and CDC123 (induced).
MAPK genes
An unexpected effect of PAR2 activation by both trypsin and
agonist peptide was seen on Mitogen-Activated Protein Kinase
(MAPK) genes. PAR2 has been frequently reported to signal
through the MAPK pathway but, in our study, ERK1 and
MAPK12 were both down-regulated up to 1.4 fold. In addition, 3
members of the dual specificity phosphatase family (DUSP1, 4, 6),
which negatively regulate members of the MAP kinase superfam-
ily, were greatly amplified by both trypsin and the agonist peptide.
DUSP6 was up-regulated 7 fold by trypsin 6 h post-treatment,
compare to 2.5 fold by PAR2 agonist. Genes in the MAP kinase
pathway that were most affected by PAR2 activation are shown in
Table 4.
Inflammatory mediators
The important inflammatory mediator cyclooxygenase-2
(COX-2) has recently been reported to be activated with induced
PAR2 expression and activation in gastric epithelial cells [41]. In
our array data, COX-2 was up-regulated 3.5 and 3 fold by trypsin
and PAR2 agonist peptide respectively (Table 5). Up-regulation of
COX-2 and other inflammatory mediators was verified by
quantitative real-time PCR (Figure 3). Other genes up-regulated
by PAR2 activation included interleukin 1 family member 9 (1.7
fold), interleukin 8 (4.5 fold) and its receptor (1.2 fold), coagulation
factor VIII (1.5 fold) and TNF-9 (1.7 fold). Interestingly, TNF-15
was instead reduced to 0.3 fold of untreated control.
Table 1. Genes regulated most strongly via PAR2 activation by either 2f-LIGRLO-NH2 (2f-O) or trypsin.
Name Gene 2f-O
2 1.5h 2f-O 3h 2f-O 6h 2f-O 12h Trypsin
3 6h
Up-Regulation
Dual Specificity phosphate 6 DUSP6 2.3
1 2.6 2.0 1.4 7.5
WW-domain-containing oxidoreductase WWOX 5.5 1.5 2.0 0.7 8
Amphiregulin preproprotein AREG 2.5 2.9 1.6 1.3 5.8
Serine proteinase inhibitor, clade B, member 2 SERPINB2 1.6 2.5 2.3 1.3 6.5
Interleukin-8 IL-8 2.4 1.9 1.3 2.8 4.5
THUMP domain containing 1 THUMPD1 4.3 2.4 2.8 1.9 2.4
Sprouty homolog 2 SPRY2 2.0 2.0 1.4 1.4 3.6
Down-Regulation
Thjoredoxin interacting protein TXNIP 0.3 0.6 0.6 0.7 0.5
Retinoic acid receptor, gamma RARG 0.6 0.4 0.8 0.7 0.3
Integrin, beta 4 ITGB4 0.6 0.6 0.9 0.8 0.3
Cathepsin D CTSD 0.7 0.6 0.9 0.7 0.3
Musculin MSC 0.5 0.6 0.8 0.7 0.3
tetraspanin 15 TM4SF15 0.5 0.3 0.7 0.7 0.9
1Expression level expressed as fold differences of control (control =1.0).
22f-O: 2f-LIGRLO-NH2 1 mM.
3Trypsin: Human Trypsin 50 nM.
doi:10.1371/journal.pone.0013809.t001
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Five genes associated with the complement pathway were
conspicuously though subtly regulated by both trypsin and PAR2
agonist peptide (Table 5). Two subunits of C1 complex, C1R and
C1QL1, were showing expression ,0.7 fold of control. Expression
of C4b, which forms C3 convertase from classical and lectin
pathways, was also ,0.7 fold of control after 12 h. In addition, a
protein responsible for C3 convertase production from the
alternative pathway, factor D, was slightly suppressed (0.8 fold of
control). On the other hand, expression of decay accelerating
factor (CD55) increased 1.3 times as a result of trypsin treatment.
Together, this data suggests that PAR2 is upstream of complement
activation and is consistent with PAR2 activation limiting
complement activation (Figure 4).
HDAC/sirtuin family
Array data showed that the expression of a number of histone
deacetylase (HDAC) genes (HDAC3, 7A, 11) was suppressed by
PAR2 activation, as were the related sirtuins 2, 3, 5 and 6 (Table 6).
Interestingly, sirtuin 1 was the only member of the HDAC/sirtuin
family that was detectably up-regulated by both trypsin (1.3 times)
and PAR2 agonist peptide (1.4 times). Moreover, the reduction in
expression of all three HDACs and sirtuin 2 was continuous for up
to 12 h after treatment, whereas the other sirtuin members slowly
returned to normal level over 12 h.
Metabolism
Of ,2500 genes regulated similarly by trypsin and PAR2
agonist peptide, more than 1000 genes are reportedly involved in
different aspects of cell metabolism, including biopolymer
metabolism (471 genes), macromolecular metabolism (687 genes)
and primary metabolism (1023 genes), with the highest number of
genes involved and the lowest p-value. Some 44 genes showing .2
fold changes are listed in Table 7 and 8. Overall, changes in
expression levels were greater for metabolism genes than for genes
in other pathways, with prolonged effects lasting up to 12 h. Genes
encoding early growth response 1 and 2 proteins were up-
regulated by PAR2 activation (EGR1 2.8x, EGR2 2x), so were the
EGR binding proteins NAB1 (2 fold) and NAB2 (4 fold). Other
Table 2. Cell cycle genes down-regulated
1 through PAR2 activation by either 2f-LIGRLO-NH2 or trypsin.
Name Gene 2f-O
2 1.5h 2f-O 3h 2f-O 6h 2f-O 12h Trypsin
3 6h
B-cell CLL/lymphoma 3 BCL3 0.6 0.8 0.9 0.9 0.7
cyclin F CCNF 0.7 0.7 0.9 0.8 0.9
cell division cycle 20 homolog CDC20 0.7 0.7 0.9 0.8 0.9
cyclin-dependent kinase (CDC2-like) 10 CDK10 0.5 0.4 0.7 0.6 0.8
cyclin-dependent kinase 5 CDK5 0.8 0.8 0.9 1.0 0.7
chromatin licensing and DNA replication factor 1 CDT1 0.7 0.7 0.8 0.8 0.8
c-src tyrosine kinase CSK 0.6 0.5 0.8 0.7 0.9
mitogen-activated protein kinase 3 ERK1 0.7 0.7 0.8 0.7 0.9
forkhead box O4 FOXO4 0.8 0.7 0.9 0.8 0.6
G protein pathway suppressor 2 GPS2 0.6 0.5 0.8 0.6 0.9
histone deacetylase 3 HDAC3 0.7 0.6 0.8 0.7 0.8
histone deacetylase 7A HDAC7A 0.5 0.4 0.7 0.6 0.9
inhibitor of growth family, member 4 ING4 0.6 0.6 0.7 0.8 0.7
inhibin, alpha INHA 0.8 0.7 0.8 0.7 0.5
jagged 2 JAG2 0.6 0.6 0.7 0.7 0.8
latent transforming growth factor beta binding protein 2 LTBP2 0.8 0.9 0.8 0.7 0.7
mitogen-activated protein kinase 12 MAPK12 0.7 0.7 0.9 0.9 0.8
meningioma (disrupted in balanced translocation) 1 MN1 0.6 0.6 0.8 0.8 0.5
N-acetyltransferase 6 NAT6 0.6 0.7 0.8 0.9 0.7
NIMA (never in mitosis gene a)- related kinase 9 NEK9 0.7 0.7 0.8 0.7 0.9
par-6 partitioning defective 6 homolog alpha PARD6A 0.5 0.5 0.7 0.8 0.7
RAD52 homolog RAD52 0.6 0.6 0.8 0.8 0.7
ras homolog gene family, member B RHOB 0.7 0.6 0.8 0.7 0.7
reprimo, TP53 dependent G2 arrest mediator candidate RPRM 0.6 0.6 0.8 0.8 0.6
septin 6 septin 6 1.0 1.0 1.0 0.9 0.7
sirtuin 2 SIRT2 0.6 0.6 0.7 0.7 0.9
tumor necrosis factor (ligand) superfamily, member 15 TNFSF15 0.6 0.7 0.8 1.4 0.3
tumor protein p53 TP53 0.8 0.8 0.8 0.7 0.9
tumor protein p73 TP73 0.6 0.7 1.0 0.8 0.5
1Expression level expressed as fold differences of control (control =1.0).
22f-O: 2f-LIGRLO-NH2 1 mM .
3Trypsin: Human Trypsin 50 nM.
doi:10.1371/journal.pone.0013809.t002
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fold of control) and telomerase reverse transcriptase (0.5 fold of
control), while protein phosphatase 2C was upregulated (3 fold) by
PAR2 activating peptide.
Genes regulated by PAR2 vs. PAR1
Modulating effects of thrombin have been reported on a small set
of genes by PAR1 activation [40]. Of those ,11,000 genes, at least
65 were induced by thrombin. We compared those 65 genes with
genes regulated by PAR2 from our study and found 4 genes that
showed the opposite trend to that reported following PAR1
activation. A further 14 genes were regulated in a similar fashion
by both PAR2 agonists (Table 9). Notably, chemokine (C-C motif)
ligand 2 expression was amplified 4 fold after treatment by either
thrombin or trypsin. Thrombospondin-1 was previously only
known to be regulated through PAR1, but our data shows that
PAR2 can also up-regulate it at a comparable level (2.5 vs 2.2 fold).
Discussion
The distinctive mode of endogenous PAR2 activation, with no
highly specific endogenous ligand known, makes it difficult to
clarify specific functions for PAR2. In this study, we used a novel
approach to identify for the first time the specific gene expression
profile induced by PAR2 activation. By comparing the gene
expression separately induced by trypsin and a PAR2 agonist
peptide, and identifying intersecting gene sets similarly up- or
down- regulated following both treatments, we can be more
confident about the effects of specific PAR2 modulation than if
either activation method was used alone.
PAR2 activation induces PAR2 expression
PAR2 expression is up-regulated following PAR2 activation. This is
logical for PAR2, as endogenous activators for the receptor are serine
proteases, which irreversibly activate PAR2 through N-terminal
cleavage. New PAR2 must therefore be produced in the cell and
expressed on the cell surface to account for the observed up-regulation
of PAR2 mRNA in response to the two extracellular PAR2 agonists.
WWOX, p73 and ITGB4
WWOX is a tumor suppressor gene [42] that shows reduced or
no expression in certain cancer models, while over-expression
induces dramatic inhibition of tumorigenicity in breast cancer.
Knock out mice develop osterosarcoma and die within 4 weeks.
WWOX associates with some proteins through its WW-domain,
attenuating translocation into the nucleus and subsequent
Table 3. Cell cycle genes up-regulated
1 through PAR2 activation by either 2f-LIGRLO-NH2 or Trypsin.
Name Gene 2f-O
2 1.5h 2f-O 3h 2f-O 6h 2f-O 12h Trypsin
3 6h
ARP1 actin-related protein 1 homolog A, centractin alpha ACTR1A 1.2 1.1 1.1 1.2 1.4
cyclin A1 CCNA1 1.3 1.9 1.7 1.3 2.1
cyclin Y-like 1 CCNYL1 1.2 1.3 1.1 1.1 1.5
cell division cycle 123 homolog CDC123 1.1 1.2 1.1 1.3 1.5
cell division cycle 25 homolog A CDC25A 2.0 1.7 1.4 1.1 1.0
dual specificity phosphatase 1 DUSP1 1.4 1.6 1.3 1.1 1.3
dual specificity phosphatase 6 DUSP6 2.3 2.6 2.0 1.4 7.5
fumarate hydratase FH 1.1 1.2 1.2 2.0 1.7
FBJ murine osteosarcoma viral oncogene homolog B FOSB 1.6 1.3 1.0 1.0 1.1
growth arrest and DNA-damage-inducible, alpha GADD45A 1.4 1.3 1.1 1.1 1.4
general transcription factor IIH, polypeptide 1 GTF2H1 1.7 1.7 1.3 1.3 1.1
interleukin 8 IL8 2.4 1.9 1.3 2.8 4.5
v-Ki-ras2 Kirsten rat sarcoma viral oncogene homolog KRAS 1.9 2.1 1.3 1.4 1.2
nucleolar and coiled-body phosphoprotein 1 NOLC1 1.9 1.8 1.7 1.6 1.3
oxidative stress induced growth inhibitor family member 2 OSGIN2 1.1 1.3 1.3 1.2 1.5
PCTAIRE protein kinase 2 PCTK2 1.2 2.0 1.0 1.3 1.4
protein phosphatase 2 (formerly 2A), alpha isoform PPP2CA 1.3 1.5 1.2 1.2 1.2
protein phosphatase 2 (formerly 2A), beta isoform PPP2CB 1.2 1.5 1.2 1.3 1.3
protein tyrosine phosphatase type IVA, member 1 PTP4A1 1.5 1.6 1.2 1.1 1.3
SERTA domain containing 1 SERTAD1 2.3 1.9 1.3 1.2 2.0
seven in absentia homolog 1 SIAH1 1.2 1.7 1.0 1.2 1.3
structural maintenance of chromosomes 3 SMC3 1.5 1.7 1.3 1.2 1.0
TAF1 RNA polymerase II TAF1 1.4 1.4 1.2 1.2 1.1
transcription factor Dp-1 TFDP1 1.1 1.2 1.3 1.4 1.2
topoisomerase (DNA) III alpha TOP3A 2.3 1.5 1.4 1.2 1.2
U2AF homology motif (UHM) kinase 1 UHMK1 1.2 1.4 1.1 1.2 1.5
1Expression level expressed as fold differences of control (control =1.0).
22f-O: 2f-LIGRLO-NH2 1 mM .
3Trypsin: Human Trypsin 50 nM.
doi:10.1371/journal.pone.0013809.t003
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tumor suppressive or oncogenic depending on isoforms of its gene
product [44]. p73 expression was downregulated herein by PAR-2
activation, along with 8 fold increases in WWOX, suggesting that
PAR-2 leads to reduced p73 transcriptional activity [43]. Further
research into effects of PAR-2 on WWOX regulation in cancer
could also be interesting as the tumor suppressor gene is up-
regulated by PAR-2, even though PAR-2 has been reported to
induce proliferation in certain carcinomas.
Integrin beta 4 (ITGB4) is a laminin receptor that is upregulated
in tumor cells and angiogenic endothelial cells [45]. Under normal
conditions, this protein regulates cellular migration and prolifer-
ation but can promote invasive growth when coupled to oncogenic
receptor tyrosine kinases. Down-regulation by PAR2 indicates a
self-regulatory effect in HEK293 cells, in line with results for the
WWOX gene. It is possible that the proliferative effect of PAR2 is
countered via regulating other genes.
AREG
The product of this gene, amphiregulin, is a member of the
epidermal growth factor family [46]. Amphiregulin is activated by
metalloproteases and can be induced by cAMP activation, and
increased levels of amphiregulin expression and release in airways,
after activation by human airway trypsin-like protease through
PAR2 receptor activation, result in mucus hypersecretion in
chronic obstructive airway disease [46]. Our array data has
demonstrated that amphiregulin expression is also substantially
induced in kidney cells by PAR2 activation and this may be
important in proliferation of kidney cells.
Cell cycle progression
PAR2 has been associated with cell proliferation in cancer and
metastasis [6,7,8,9]. Our finding of differential up- and down-
regulation of genes associated with the cell cycle was surprising to
us, and contrary to an expectation of up-regulation of genes
Figure 2. Cell cycle genes regulated by PAR2 (red, up-regulated; blue, down-regulated; black, other related genes). Among key cell
cycle components modulated were p53, the cyclin family, and the cdk family. The influence on cell cycle progression is not clear despite reports of
PAR2 in cell proliferation.
doi:10.1371/journal.pone.0013809.g002
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Name Gene 2f-O
2 1.5h 2f-O 3h 2f-O 6h 2f-O 12h Trypsin
3 6h
Down-Regulation
adrenergic, alpha-2C-, receptor ADRA2C 0.5
1 0.6 0.7 0.6 0.5
CD81 molecule CD81 0.8 0.7 1.0 0.8 0.8
dual specificity phosphatase 10 DUSP10 0.8 0.8 0.8 0.7 0.9
mitogen-activated protein kinase 3 ERK1 0.7 0.7 0.8 0.7 0.9
Mitogen-activated protein kinase 12 MAPK12 0.7 0.7 0.9 0.9 0.8
fibroblast growth factor receptor 3 FGFR3 0.8 0.8 0.8 0.9 0.9
growth arrest and DNA-damage-inducible, gamma GADD45G 0.6 0.5 0.8 0.8 0.7
G protein pathway suppressor 1 GPS1 0.8 0.8 0.9 0.8 0.8
G protein pathway suppressor 2 GPS2 0.6 0.5 0.8 0.6 0.9
neurturin NRTN 0.6 0.7 0.7 0.7 0.8
Up-Regulation
regulator of G-protein signalling 4 RGS4 1.5 1.2 1.3 1.1 2.2
dual specificity phosphatase 1 DUSP1 1.4 1.6 1.3 1.1 1.3
dual specificity phosphatase 4 DUSP4 1.2 1.1 1.1 1.3 1.3
dual specificity phosphatase 6 DUSP6 2.3 2.6 2.0 1.4 7.5
mitogen-activated protein kinase kinase 4 MAP2K4 1.2 1.4 1.1 1.1 1.4
MAP3K12 binding inhibitory protein 1 MBIP 1.1 1.3 1.0 1.1 1.2
p21/Cdc42/Rac1-activated kinase 1 PAK1 1.6 1.5 1.4 1.4 1.3
protein phosphatase 2 (formerly 2A), alpha isoform PPP2CA 1.3 1.5 1.2 1.2 1.2
protein phosphatase 2 (formerly 2A), beta isoform PPP2CB 1.2 1.5 1.2 1.3 1.3
1Expression level expressed as fold differences of control (control =1.0).
22f-O: 2f-LIGRLO-NH2 1 mM.
3Trypsin: Human Trypsin 50 nM.
doi:10.1371/journal.pone.0013809.t004
Table 5. PAR2 activated genes associated with inflammation induced by either 2f-LIGRLO-NH2 or Trypsin.
Name Gene 2f-O
2 1.5h 2f-O 3h 2f-O 6h 2f-O 12h Trypsin
3 6h
Genes involved in Inflammatory and Immune response
prostaglandin-endoperoxide synthase 2 COX-2 3.1
1 1.9 1.2 1.2 3.4
Interleukin 8 Precusor IL-8 2.4 1.9 1.3 2.8 4.5
Interleukin 1 family, member 9 IL1F9 1.4 1.2 1.2 1.1 1.8
Interleukin 8 Receptor IL8R 1.0 1.3 1.1 1.2 1.2
fibrinogen gamma chain FGG 1.8 1.5 1.5 1.4 1.2
coagulation factor VIII F8 1.5 1.2 1.0 1.0 1.4
TNF superfamily, member 9 TNF9 1.4 1.2 1.1 1.1 1.7
Complement Pathway
CD55 molecule CD55 1.2 1.3 1.0 1.0 1.3
complement component 1, q subcomponent like C1QL1 0.7 0.7 0.8 0.8 1.0
complement component 1, r subcomponent C1R 0.8 0.8 0.8 0.7 0.9
complement component 4B C4B 0.7 0.7 0.7 0.7 0.7
complement factor D CFD 0.8 0.9 0.9 1.0 0.8
1Expression level expressed as fold differences of control (control =1.0).
22f-O: 2f-LIGRLO-NH2 1 mM.
3Trypsin: Human Trypsin 50 nM.
doi:10.1371/journal.pone.0013809.t005
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PLoS ONE | www.plosone.org 7 November 2010 | Volume 5 | Issue 11 | e13809Figure 3. Correlation between microarray gene expression and qRT-PCR. HEK293 cells were treated with trypsin or 2f-LIGRLO-NH2 and total
RNA was extracted 6 h later. Data represent the average of 3 independent experiments. Columns (negative control, white; 2f-LIGRLO-NH2, grey;
trypsin, black) show representative regulation of PAR2, DUSP6, WWOX, ITGB4, p73, Amphiregulin, SERPINB2, Il-8 precursor, ERK-1, COX-2, TNF-9, TNF-
15, HDAC-7A, EGR-1 and EGR-2 by PAR2 activation. Results from qRT-PCR were compared to microarray data at equal times.
doi:10.1371/journal.pone.0013809.g003
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except that there would seem to be no single message for, or
against, proliferation. Thus, the precise role of PAR2 activation in
proliferation at least in HEK293 cells remains obscure based on
microarray data alone.
MAPK pathway
PAR2 activation also unexpectedly down-regulated expression
of MAPK associated genes, including ERK-1. PAR2 is known to
couple to Gi, and both ERK and MEK are signal transducers in
the Gi signaling cascade. There was also a strong (7-fold)
upregulation of DUSP6, a negative regulator for the MAPK
superfamily, after treatment with trypsin. Other DUSP family
members affected included DUSP1, 4 and 10. DUSP4 specifically
targets JNK, and both DUSP1 and 10 have demonstrated roles in
inflammation. To our knowledge, PAR2 has not previously been
reported to negatively regulate the MAPK pathway.
Complement regulation
Another surprise was that PAR2 activation led to some
differential expression of 5 key genes associated with complement
activation (Figure 4). Complement genes 1r and 4a, which are
particularly important for complement activation via the classical
pathway, were slightly down-regulated, suggesting that PAR2
activation indirectly leads to inhibition of the classical pathway of
complement activation. Similarly, factor D which is crucial for
forming the C3 convertase that is pivotal for complement activation
by classical, lectin and alternative pathways, was also slightly down-
regulated (0.8 fold of control) by PAR2 activation. Interestingly, the
decay accelerating factor (CD55) which has the reverse effect in
complement pathways was up-regulated by PAR2. Together these
findings support anti-complement properties for PAR2, consistent
with an anti-inflammatory role at least for the kidney cells studied
here. Also, as a consequence of acting as an upstream negative
regulator of complement activation, PAR2 activation is expected to
reduce formation of the pro-inflammatory anaphylatoxins (C3a,
C4a, C5a) as well as membrane attack complex (MAC) required for
host-mediated destruction of infectious organisms.
Other inflammatory mediators
PAR2 activation reportedly displays both pro- [14,17] and anti-
inflammatory [10,12,13,15,16] responses in different disease
models, including asthma, arthritis, and irritable bowel syndrome.
These seemingly paradoxical roles for PAR2 in inflammation have
been based mainly on observations of PAR2-activating peptides
with low potency and uncertain receptor selectivity, and so there
remains doubt about whether both pro- and anti- inflammatory
properties can truly be ascribed to PAR2 activation. To date, the
mechanisms that PAR2 uses to mediate these inflammatory
responses have not been fully elucidated, but if PAR2 really is both
pro- and anti- inflammatory these properties may be highly
context and cell dependent.
Cyclooxygenase-2 expression was found here to be significantly
amplified by PAR2 activation. COX-2 is an important downstream
pro-inflammatory mediator. Up-regulation of this and other
inflammatory mediators (e.g. IL-8 and receptor, IL-1, TNF-9) is
consistent with a pro-inflammatory role for PAR2 activation, in
contrast to the anti-inflammatory complement effects above. This is
the first time at the transcriptional level that PAR2 has been shown
Figure 4. Effects of PAR2 activation on complement pathways.
Relationship between genes regulated by PAR2 (black arrows) and
classical, alternative and lectin pathways of complement activation. Five
key genes regulated by PAR2 activation were C1q, C1r, C4b, factor D
and CD55 (decay accelerating factor). C1r/q subunits of C1 are in the
classical pathway; C4b is essential for formation of C3 convertase in the
classical and lectin pathways; Factor D is similarly important for C3
convertase in the alternative pathway; CD55 actively breaks down C3
convertase contributing to anti-complement effects of PAR2. Such
regulation of all these genes will limit formation of pro-inflammatory
anaphylatoxins (C3a, C5a) and membrane attack complex.
doi:10.1371/journal.pone.0013809.g004
Table 6. Transcriptional regulation
1 of HDAC and sirtuin
enzymes by PAR2 activation via either 2f-LIGRLO-NH2 or
Trypsin.
Gene Name
2f-O
2
1.5h
2f-O
3h
2f-O
6h
2f-O
12h
Trypsin
3
6h
Histone Acetyltransferase-1 1.1 1.2 1.1 1.3 1.2
HDAC family
histone deacetylase 1 1.0 1.0 0.9 0.9 0.9
histone deacetylase 2 1.0 1.1 1.0 0.9 1.1
histone deacetylase 3 0.7 0.6 0.8 0.7 0.8
histone deacetylase 4 0.8 0.6 0.8 0.6 1.3
histone deacetylase 5 0.8 0.9 0.9 0.9 0.9
histone deacetylase 6 0.9 0.9 0.8 1.0 0.9
histone deacetylase 7A 0.5 0.4 0.7 0.6 0.9
histone deacetylase 8 1.3 1.2 1.2 1.2 0.9
histone deacetylase 9 1.1 1.1 0.8 1.2 1.5
histone deacetylase 11 0.6 0.6 0.8 0.7 0.6
Sirtuin family
sirtuin 1 1.3 1.4 1.0 1.0 1.3
sirtuin 2 0.6 0.6 0.7 0.7 0.9
sirtuin 3 0.8 0.7 0.9 0.8 0.6
sirtuin 4 0.9 0.9 1.0 1.0 1.1
sirtuin 5 0.9 0.9 0.9 1.0 0.8
sirtuin 6 0.8 0.8 1.0 1.0 0.8
sirtuin 7 1.0 0.9 0.9 0.9 0.9
1Expression level expressed as fold differences of control (control =1.0).
2Peptide: 2f-LIGRLO-NH2 1 mM.
3Trypsin: Human Trypsin 50 nM.
doi:10.1371/journal.pone.0013809.t006
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line and is consistent with the notion that PAR2 activation could be
pro- or anti- inflammatory depending upon circumstances. Which
physiological response is exhibited may indeed be a function of cell/
tissue type and the environmental concentrations of receptors/
inhibitors capable of masking inflammatory responses.
Histone deacetylases (HDACs) and their inhibitors have been
associated with both pro- and anti-inflammatory roles and are
being increasingly associated with inflammation [47,48]. Inhibitors
have been found to exhibit potential therapeutic roles in rat
adjuvant- [49] and mouse antibody- [50] induced arthritis, mouse
inflammatory renal disease [51], airways inflammation in mice
[52], experimental autoimmune encephalomyelitis [53], and
COPD [54]. Up-regulation of HDACs by lipopolysaccharide
(LPS) or use of some HDAC inhibitors (particularly inhibitors of
class I HDACs) results in amplified expression of proinflammatory
genes such as COX-2 [55]. This is particularly relevant to, and
consistent with, findings in the present study where PAR2
activation leads to up-regulation of certain class I HDACs (HDAC
3, 11) and class II HDACS (HDAC 7), as well as up-regulation of
pro-inflammatory genes such as COX-2.
Metabolism
There is almost no literature on PAR2 activation and metabolism,
yet the results herein showed that ,50% of genes regulated by PAR2
activation in kidney cellsare involved in metabolism.The significance
of this new observation for PAR2 activation in terms of cellular and
physiological mechanisms remains to be elucidated, but points to the
need for studies that investigate PAR2 regulation in both normal
metabolism and metabolic dysfunction.
PAR2 versus PAR1
PAR1 is activated in a similar manner to PAR2 by proteases
(thrombin, other coagulation proteases, different activating
hexapeptides). It has been closely linked to the coagulation
cascade and platelet activation, which is critical for hemostasis and
thrombosis. PAR1 was recently implicated in tumor progression,
especially cancer metastasis and angiogenesis [4]. This is consistent
with findings in the present microarray study, where 14 genes that
were up-regulated by PAR1 [40] were also up-regulated by PAR2.
Of these, 9 genes are involved in regulation of tumorigenesis, a
finding which suggests that PAR1 and PAR2 may share some
common key signaling pathways in cancer. In addition, throm-
bospondin-1 is up-regulated by PAR2 activation. THBS-1 is a
large extracellular matrix glycoprotein shown to cause platelet
activation, angiogenesis and wound healing. Previously, it was
known to be only activated by PAR1, but now we suggest that
PAR2 can also trigger expression of thrombospondin-1.
Conclusions
The present study provides a valuable and decisive platform
upon which to base new hypotheses and pharmacological studies
Table 7. PAR2 activated genes involved in metabolism down-regulated by either 2f-LIGRLO-NH2 or Trypsin.
Name Gene 2f-O
2 1.5h 2f-O 3h 2f-O 6h 2f-O 12h Trypsin
3 6h
ATP-binding cassette, sub-family A, member 2 ABCA2 0.5 0.5 0.7 0.6 0.6
Aldehyde dehydrogenase 1 family, member A3 ALDH1A3 0.8 0.8 0.6 0.7 0.4
ATPase, Ca++ transporting, ubiquitous ATP2A3 0.6 0.7 0.7 0.7 0.5
Cyclin-dependent kinase (CDC2-like) 10 CDK10 0.5 0.4 0.7 0.6 0.8
Cathepsin D CTSD 0.7 0.6 0.9 0.7 0.3
2,4-dienoyl CoA reductase 2, peroxisomal DECR2 0.6 0.5 0.7 0.6 0.9
EPH receptor B4 EPHB4 0.6 0.5 0.8 0.6 0.8
Epoxide hydrolase 2, cytoplasmic EPHX2 0.6 0.6 0.7 0.6 0.5
Histone deacetylase 7A HDAC7A 0.5 0.4 0.7 0.6 0.9
3-hydroxymethyl-3-methylglutaryl-Coenzyme A lyase HMGCL 0.6 0.5 0.7 0.7 0.8
Hydroxy-delta-5-steroid dehydrogenase, 3 beta- and steroid
delta-isomerase 7
HSD3B7 0.7 0.6 0.7 0.7 0.5
Inositol polyphosphate-5-phosphatase INPP5D 0.6 0.7 0.6 0.6 0.5
PCTAIRE protein kinase 3 PCTK3 0.5 0.4 0.7 0.6 0.8
Protein disulfide isomerase family A, member 2 PDIA2 0.6 0.7 0.7 0.8 0.5
Protein tyrosine phosphatase, non-receptor type 6 PTPN6 0.4 0.4 0.5 0.5 0.8
Solute carrier family 7 (cationic amino acid transporter,
y+ system), member 8
SLC7A8 0.8 0.7 0.8 0.7 0.4
SMAD family member 6 SMAD6 0.6 0.6 0.7 0.8 0.5
Telomerase reverse transcriptase TERT 0.7 0.8 0.8 1.0 0.5
Tyrosine kinase, non-receptor, 2 TNK2 0.6 0.4 0.6 0.6 0.8
Tumor protein p73 TP73 0.6 0.7 1.0 0.8 0.5
TSC22 domain family, member 3 TSC22D3 0.6 0.6 0.6 0.7 0.4
Zinc finger and BTB domain containing 16 ZBTB16 0.6 0.5 0.7 0.8 0.8
1Expression level expressed as fold differences of control (control =1.0).
22f-O: 2f-LIGRLO-NH2 1 mM.
3Trypsin: Human Trypsin 50 nM.
doi:10.1371/journal.pone.0013809.t007
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and disease. It is clear from this study that PAR2 activation is self-
sustaining and strongly implicated in cell metabolism, proliferation
and inflammation. The study particular highlights the need for
new research on PAR2 in metabolism and metabolic dysfunction.
Tumour and growth factor genes like WWOX, p73, ITGB4 and
AREG were strongly up-regulated by PAR2 activation, supporting
roles for PAR2 in proliferation, tumour growth and, perhaps
surprisingly, also tumour suppression. The evidence for anti-
inflammatory (anti-complement) and pro-inflammatory (COX2,
HDACs, IL8, IL1, TNF, DUSP1, DUSP10, AREG) effects in
HEK293 cells is the first evidence at the gene expression level for a
dual capacity of PAR2 in regulating inflammatory pathways that
may have important implications in the kidney and possibly in
kidney-related disease. These observations validate to some extent
the seemingly paradoxical literature on possible pro- and anti-
inflammatory roles for PAR2, which have been simultaneously
witnessed here at the transcriptional level in the one cell line.
Finally, some genes were expressed with similar profiles following
activation by either PAR1 or PAR2, these mainly being associated
with tumorigenesis and cancer progression, implicating a possible
sharing of proliferative mechanisms between these two receptors
on cell surfaces. This study supports the idea that both PAR2
agonists and antagonists might have valuable therapeutic roles in
different tissues and encourages the development of both agonists
and especially antagonists that are selective for PAR2 as potential
new therapies for cancers and inflammatory conditions.
Materials and Methods
Cell Culture
HEK293 cells were maintained in DMEM with 10% fetal
bovine serum, penicillin/streptomycin (5000 units/mL; 5000 mg/
mL), 1X Non-Essential Amino Acid, and L-glutamine in 95% air/
5% CO2 at 37uC. The cells were seeded at 16105 cells/mL and
subcultured after detachment with 0.05% trypsin/0.5 mM EDTA.
Cell culture reagents were purchased from Invitrogen, USA.
HEK293 treatment
Cells were grown to 90% confluence, switched to serum free
medium containing 0.03% bovine serum albumin (BSA), and
incubated for 3 h. Cells were then treated with either 50 nM
trypsin (Invitrogen, USA), 1 mM PAR2 agonist peptide (2f-
LIGRLO-NH2; synthesized in-house) or vehicles (phosphate
buffered saline, pH 7.4) and incubated for additional 90 min, 3,
6 or 12 hours. Cells were then washed three times with cold PBS,
ready for RNA extraction.
RNA extraction and reverse transcription
Total RNA was extracted from cells using an RNeasy mini kit
(Qiagen, USA) and following manufacturer’s instructions. RNA
was checked on an agarose gel for quality and concentration
determined by measuring absorbance at l=260/280 nm on a
spectrophotometer. Total RNA was then reverse transcripted with
Superscript III (Invitrogen, USA) using random oligo dT primer.
Table 8. PAR2 activated genes involved in metabolism up-regulated by either 2f-LIGRLO-NH2 or Trypsin.
Name Gene 2f-O
2 1.5h 2f-O 3h 2f-O 6h 2f-O 12h Trypsin
3 6h
Acyl-CoA synthetase long-chain family member 4 ACSL4 2.0
1 2.1 1.5 1.4 1.6
Catenin (cadherin-associated protein), beta 1 CTNNB1 2.2 1.5 1.4 1.2 1.5
Discs, large homolog 1 DLG1 2.4 1.4 1.3 1.1 1.5
Dual specificity phosphatase 6 DUSP6 2.3 2.6 2.0 1.4 7.5
Early growth response 1 EGR1 2.8 2.0 1.8 1.1 2.5
Early growth response 2 EGR2 2.1 1.5 1.1 1.0 1.7
Ets variant gene 4 (E1A enhancer binding protein, E1AF) ETV4 1.3 1.4 2.0 1.3 2.7
Exosome component 3 EXOSC4 1.3 2.1 1.3 1.2 1.9
3-hydroxy-3-methylglutaryl-Coenzyme A synthase 1 (soluble) HMGCS1 1.6 1.8 1.5 2.1 1.9
Homer homolog 1 HOMER1 2.4 2.2 1.0 0.9 1.7
Inhibitor of DNA binding 4, dominant negative helix-loop-helix protein ID4 1.5 1.6 1.2 1.4 2.6
Kruppel-like factor 5 (intestinal) KLF5 2.2 2.1 1.5 1.3 1.6
Myeloid/lymphoid or mixed-lineage leukemia (trithorax homolog,
Drosophila)
MLLT 2.0 1.8 1.1 1.4 1.2
Matrix metallopeptidase 3 MMP3 1.3 1.5 1.5 1.0 2.2
NGFI-A binding protein 1 (EGR1 binding protein 1) NAB1 2.1 2.2 1.2 1.3 1.4
NGFI-A binding protein 2 (EGR1 binding protein 2) NAB2 4.0 2.3 2.5 1.4 2.1
Oligodendrocyte lineage transcription factor 2 OLIG2 2.2 2.4 1.4 1.2 1.7
Protein phosphatase 2C, magnesium-dependent, catalytic subunit PPM2C 2.9 1.9 1.5 1.4 1.3
prostaglandin-endoperoxide synthase 2 (COX-2) PTGS2 3.1 1.9 1.2 1.2 3.4
Protein tyrosine phosphatase, non-receptor type 14 PTPN14 2.2 2.3 2.0 2.1 1.4
Topoisomerase (DNA) III alpha TOP3A 2.3 1.5 1.4 1.2 1.2
Zinc finger and BTB domain containing 43 ZBTB43 2.4 1.9 1.4 1.2 1.2
1Expression level expressed as fold differences of control (control =1.0).
22f-O: 2f-LIGRLO-NH2 1 mM.
3Trypsin: Human Trypsin 50 nM.
doi:10.1371/journal.pone.0013809.t008
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15 min, 70uC.
Gene Expression Profiling
Arrays were obtained from the SRC Microarray Facility,
University of Queensland (ARC Centre for Functional and
Applied Genomics) and comprised 18,664 human gene-specific
oligo-nucleotides spotted on coated slides. All samples were
compared to controls in triplicate, with one of three hybridizations
involving a dye reversal. Total RNA underwent one rounds of
linear amplification using MessageAmp aRNA Kit (Ambion Inc.
TX, USA). For each comparison, 2 mg of amplified RNA was
labelled with Cy3-dUTP or Cy5-dUTP (Amersham Biosciences,
Australia). Cy3 and Cy5 hybridization signals were collected using
the Agilent 600B Array Scanner. Intensity and background data
for each element were calculated using Imagene 5.5 (BioDiscovery
Inc., Australia).
Data Analysis
Microarray data were analyzed as described [56]. Briefly,
microarray data were imported and the entire dataset is available
from NCBI via the GEO database (accession number:
GSE24332). Raw data from each hybridization was compiled
and subjected to print tip intensity independent Lowess normal-
ization using the R statistical software package data and analyzed
using LIMMA (http://bioinf.wehi.edu.au/limma/). This normal-
ization was implemented in BASE using scripts developed by Ola
Spjuth of Linnaeus Centre for Bioinformatics (http://www.lcb.uu.
se/baseplugins.php). Normalized values were used to calculate B-
statistics, which were analyzed with allowance for the correlation
between adjacent duplicate spots printed on the same array.
Differential expression was defined using a robust statistical
method rather than simple fold change. All genes were ranked
using B-statistics where both fold change and variance of signals in
replicates was used to determine the likelihood that genes were
truly differentially expressed. A B-score .0 for a gene translates to
a .50% probability of being truly differentially expressed. This
analysis was executed using the Bio-conductor package as a plug in
tool in BASE. Full documentation of the array fabrication, gene
content, experimental procedures and all results are available in
accordance with MIAME (http://www.mged.org/ Workgroups/
MIAME/miame.html) guidelines at http://kidney.scgap.org/
base. Genes similarly regulated by both treatments were annotated
and compared using Database for Annotation, Visualisation and
Intergrated Discovery (DAVID, http://david.abcc.ncifcrf.gov/).
Quantitative RT-PCR
Duplicate samples were treated with trypsin (50 nM) or PAR2
agonist (1 mM) for 6 h. Total RNA was extracted and reverse
transcripted as outlined. 50 ng of cDNA was incubated with
reagents and relevant primers as listed. PAR2: forward primer, 59
GGG TTT GCC AAG TAA CGG C 39, reverse primer, 59 GGG
AAC CAG ATG ACA GAG AGG 39; DUSP6: forward primer,
59 ATC ACT GGA GCC AAA ACC TG 39, reverse primer, 59
CAG CCA AGC AAT GTA CCA AG 39; WWOX: forward
primer, 59 GAA AAC GAG TGG CAG GAG AT 39, reverse
Table 9. Genes regulated by both PAR1 and PAR2 activation.
PAR1
2 PAR2 2f-O
3 Trypsin
4
Name Gene 1.5h 6h 12h 1.5h 3h 6h 12h 6h
Opposite Regulation
retinol dehydrogenase 5 RDH1 1.5
1 1.4 1.6 0.8 0.9 0.8 0.9 0.8
cyclin D2 CCND2 1.4 2.4 2.5 0.9 0.7 0.8 0.8 0.8
smoothelin SMTN 1.1 1.5 1.6 0.7 0.6 0.9 0.7 0.6
ras homolog gene family, member B RHOB 1.5 1.9 1.4 0.7 0.6 0.8 0.7 0.7
Similar Regulation
monoglyceride lipase MGLL 1.2 1.6 1.9 1.0 1.2 1.0 1.1 1.2
uridine-cytidine kinase 2 UMPK 1.2 1.5 1.7 1.1 1.2 1.2 1.2 1.3
CD44 molecule CD44 1.1 1.0 1.7 1.6 1.3 1.1 1.1 1.3
FOS-like antigen 1 FOSL1 1.8 1.7 1.4 1.2 1.2 1.2 1.1 2.0
TNF receptor superfamily, member 12a TNFRSF12A 2.1 2.1 2.1 1.2 1.1 1.2 1.1 1.3
RAB3A, member RAS oncogene family RAB3A 1.9 1.7 1.4 1.1 1.2 1.0 0.8 1.3
Kruppel-like factor 6 COPEB 1.6 1.6 1.3 1.1 1.2 1.1 1.2 1.1
chemokine (C-C motif) ligand 2 CCL2 2.7 4.0 2.1 1.7 1.8 1.2 1.4 4.2
gremlin 1 CKTSF1B1 1.2 2.1 2.1 1.3 1.5 1.2 1.1 2.8
coronin, actin binding protein, 1C CORO1C 1.2 2.0 1.8 1.2 1.1 1.1 0.9 1.5
thrombospondin 1 THBS1 1.2 2.5 1.9 2.1 2.2 1.3 1.2 1.6
syndecan 4 SDC4 2.0 1.4 1.5 1.1 1.1 1.2 1.1 2.3
immediate early response 3 IER3 2.4 1.8 1.8 1.2 1.0 1.1 1.1 1.4
connective tissue growth factor CTFG 2.4 1.9 1.5 1.6 1.3 1.2 1.1 1.9
1Expression level expressed as fold differences of control (control =1.0).
2PAR1 results extracted from McLaughlin et.al. (2005) J.Biol.Chem.280:22172-22180.
3PAR2 2f-O: 2f-LIGRLO-NH2 1 mM.
4Trypsin: Human Trypsin 50 nM.
doi:10.1371/journal.pone.0013809.t009
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forward primer, 59 GGC AAC CGG GAC TAC ATC C 39,
reverse primer, 59 CGC AGG AGG GAG TCA ACT T 39; p73:
forward primer, 59 GTC AAG CCG GGG GAA TAA TGA 39,
reverse primer, 59 CTC AGC AGA TTG AAC TGG GC 39;
Amphiregulin: forward primer, 59 GTC CTC GGG AGC CGA
CTA T 39, reverse primer, 59 GGG GGC TTA ACT ACC TGT
TCA A 39; SERPINB2: forward primer 59 ATG CAG TTA CCC
CCA TGA CT 39, reverse primer, 59 CGC ATC AGG ATA ACT
ACC CTT C 39; IL-8 precursor: forward primer, 59 AAG AAA
CCA CCG GAA GGA AC 39, reverse primer, 59 AGC TGC
AGA AAT CAG GAA GG 39; ERK-1: forward primer 59 CTG
GAT CAG CTC AAC CAC ATT 39, reverse primer 39 AGA
GAC TGT AGG TAG TTT CGG G 39; COX-2: forward
primer, 59 ATA TGT TCT CCT GCC TAC TGG AA 39, reverse
primer, 59 GCC CTT CAC GTT ATT GCA GAT G 39; TNF-9:
forward primer, 59 TGG TGG CCC AAA ATG TTC TG 39,
reverse primer, 59 AGA AGA CAT AGT AGA CTC CAG CC 39;
TNF-15: forward primer, 59 CTT GCA GGA CTC ACC ACA
TAC 39, reverse primer, 59 CGT CTG CTC TAA GAG GTG
CAT 39; HDAC7A: forward primer, 59 AGA GCA AGC GAA
GTG CTG TAG 39, reverse primer, 59 GGG CTC CAG GGT
TCT GTA G 39; EGR-1: forward primer, 59 ACC TGA CCG
CAG AGT CTT TTC 39, reverse primer, 59 GCC AGT ATA
GGT GAT GGG GG 39; EGR-2: forward primer, 59 GCC AAG
GCC GTA GAC AAA ATC 39, reverse primer, 59 CCA CTC
CGT TCA TCT GGT CA 39. PCR was run on ABI PRISM 7000
(Applied Biosystem, Australia) with the following cycle conditions:
50uC for 2 min, 95uC for 10 min then 40 cycles of 95uC for 15 s
and 60uC for 1 min, completed with 25uC for 2 min. Fluorescence
data was collected during the extension phase (60uC). Raw real
time data was analyzed using ABI Prism 2000 SDS v2.0 software
(Applied Biosystem, Australia).
Acknowledgments
We thank Dr. Grant Barry for providing 2f-LIGRLO-NH2 and Dr. Maria
Halili for assistance with some RT-PCR experiments.
Author Contributions
Conceived and designed the experiments: JYS DF. Performed the
experiments: JYS BG. Analyzed the data: JYS BG SMG. Contributed
reagents/materials/analysis tools: SMG DF. Wrote the paper: JYS.
Reviewed and edited paper: DF.
References
1. Elefsinioti AL, Bagos PG, Spyropoulos IC, Hamodrakas SJ (2004) A database for
G proteins and their interaction with GPCRs. BMC Bioinformatics 5: 208–215.
2. Schioth HB, Fredriksson R (2005) The GRAFS classification system of G-
protein coupled receptors in comparative perspective. General and Comparative
Endocrinology 142: 94–101.
3. Hill SJ (2006) G-protein-coupled receptors: past, present and future. British
Journal of Pharmacology 147: S27–S37.
4. Barry GD, Le GT, Fairlie DP (2006) Agonists and antagonists of protease
activated receptors (PARs). Current Medicinal Chemistry 13: 243–265.
5. Steinhoff M, Buddenkotte J, Shpacovitch V, Rattenholl A, Moormann C, et al.
(2005) Proteinase-Activated Receptors: Transducers of Proteinase-Mediated
Signaling in Inflammation and Immune Response. Endocrine Reviews 26: 1–43.
6. Shimamoto R, Sawada T, Uchima Y, Inoue M, Kimura K, et al. (2004) A role
for protease-activated receptor-2 in pancreatic cancer cell proliferation.
International Journal of Oncology 24: 1401–1406.
7. Darmoul D, Gratio V, Devaud H, Laburthe M (2004) Protease-activated
Receptor 2 in colon cancer. Journal of Biological Chemistry 279: 20927–20934.
8. Masamune A, Kikuta K, Satoh M, Suzuki N, Shimosegawa T (2005) Protease-
activated receptor-2 mediated proliferation and collagen production of rat
pancreatic stellate cells. Journal of Pharmacology and Experimental Therapeu-
tics 312: 651–658.
9. Wilson S, Greer B, Hooper J, Zijlstra A, Walker B, et al. (2005) The membrane-
anchored serine protease, TMPRSS2, activates PAR-2 in prostate cancer cells.
Biochemical Journal 388: 967–972.
10. Holzhausen M, Spolidorio L, Vergnolle N (2005) Role of protease-activated
receptor-2 in inflammation, and its possible implications as a putative mediator
of periodontitis. Memorias do Instituto Oswaldo Cruz 100: 177–180.
11. Buddenkotte J, Stroh C, Engels IH, Moormann C, Shpacovitch VM, et al.
(2005) Agonists of proteinase-activated receptor-2 stimulate upregulation of
Intercellular Cell Adhesion Molecule-1 in primary human keratinocytes via
activation of NH-kappa B. Journal of Investigative Dermatology 124: 38–45.
12. Hansen KK, Sherman PM, Cellars L, Andrade-Gordon P, Pan Z, et al. (2005) A
major role for proteolytic activity and proteinase-activated receptor-2 in the
pathogenesis of infectious colitis. Proceeding of National Academy of Science
USA 102: 8363–8368.
13. Lee YCG, Knight DA, Lane KB, Cheng DS, Koay MA, et al. (2005) Activation
of proteinase-activated receptor-2 in mesothelial cells induces pleural inflam-
mation. American Journal of Physiology Lung Cellular and Molecular
Physiology 288: 734–740.
14. Maeda K, Hirota M, Kimura Y, Ichihara A, Ohmuraya M, et al. (2005)
Proinflammatory Role of Trypsin and Protease-activated Receptor-2 in a Rat
Model of Acute Pancreatitis. Pancreas 31: 54–62.
15. Reed CE, Kita H (2004) The role of protease activation of inflammation in
allergic respiratory diseases. Journal of Allergy and Clinical Immunology 114:
997–1008.
16. Campo BAD, Henry PJ (2005) Stimulation of protease-activated receptor-2
inhibits airway eosinophilia, hyperresponsiveness and bronchoconstriction in a
murine model of allergic inflammation. British Journal of Pharmacology 144:
1100–1108.
17. Fiorucci S, Mencarelli A, Palazzetti B, Distrutti E, Vergnolle N, et al. (2001)
Proteinase-activated receptor 2 is an anti-inflammatory signal for colonic lamina
propria lymphocytes in a mouse model of colitis. Proceeding of National
Academy of Science USA 98: 13936–13941.
18. Jacob C, Yang P-C, Darmoul D, Amadesi S, Saito T, et al. (2005) Mast cell
tryptase controls paracellular permeability of the intestine: role of protease-
activated receptor 2 and b-arrestins. Journal of Biological Chemistry.
19. Hjortoe GM, Petersen LC, Albrektsen T, Sorensen BB, Norby PL, et al. (2004)
Tissue factor-factor VIIa-specific up-regulation of IL-8 expression in MDA-MB-
231 cells is mediated by PAR-2 and results in increased cell migration. Blood
103: 3029–3037.
20. Johansson U, Lawson C, Dabare M, Syndercombe-Court D, Newland AC, et al.
(2005) Human peripheral blood monocytes express protease receptor-2 and
respond to receptor activation by production of IL-6, IL-8 and IL-1b. Journal of
Leukocyte Biology 78.
21. Shichijo M, Kondo S, Ishimori M, Watanabe S, Helin H, et al. (2006) PAR-2
deficient CD4+ T cells exhibit downregulation of IL-4 and upregulation of IFN-
c after antigen challenge in mice. Allergology International 55: 271–278.
22. Takizawa T, Tamiya M, Hara T, Matsumoto J, Saito N, et al. (2005)
Abrogation of Bronchial Eosinophilic Inflammation and Attenuated Eotaxin
Content in Protease-Activated Receptor 2-Deficient Mice. Journal of Pharma-
cological Science 98: 99–102.
23. Lindner JR, Kahn ML, Coughlin SR, Sambrano GR, Schauble E, et al. (2000)
Delayed onset of inflammation in protease-activated receptor-2-deficient mice.
Journal of Immunology 165: 6504–6510.
24. Cicala C (2002) Protease activated receptor 2 and the cardiovascular system.
British Journal of Pharmacology 135: 14–20.
25. Kawabata A, Oono Y, Yonezawa D, Hiramatsu K, Inoi N, et al. (2005) 2-
Furoyl-LIGRL-NH2, a potent agonist for proteinase-activated receptor-2, as a
gastric mucosal cytoprotective agent in mice. British Journal of Pharmacology
144: 212–219.
26. Kawabata A (2003) Gastrointestinal functions of proteinase-activated receptors.
Life Sciences 74: 247–254.
27. Schmidlin F, Amadesi S, Vidil R, Trevisani M, Martinet N, et al. (2001)
Expression and function of proteinase-activated receptor 2 in human bronchial
smooth muscle. American Journal of Respiratory and Critical Care Medicine
164: 1276–1281.
28. Fiorucci S, Antonelli E, Distrutti E, Severino B, Fiorentina R, et al. (2004) PAR1
antagonism protects against experimental liver fibrosis. Role of proteinase
receptors in stellate cell activation. Hepatology 39: 365–375.
29. Gaca MDA, Zhou X, Benyon RC (2002) Regulation of hepatic stellate cell
proliferation and collagen synthesis by proteinase-activated receptors. Journal of
Hepatology 36: 362–369.
30. Stenton G, Nohara O, Dery R, Vliagoftis H, Gilchrist M, et al. (2002)
Proteinase-activated receptor (PAR)-1 and -2 agonists induce mediator release
from mast cells by pathways distinct from PAR-1 and PAR-2. J Pharmacol Exp
Ther 302: 466–474.
31. Zhao A, Shea-Donohue T (2003) PAR-2 agonists induce contraction of murine
small intestine through neurokinin receptors. Am J Physiol Gastrointest Liver
Physiol 285: G696–703.
32. Abey HT, Fairlie DP, Moffatt JD, Balzary RW, Cocks TM (2006) Protease-
Activated Receptor-2 peptides activate Neurokinin-1 receptors in the mouse
isolated trachea. Journal of Pharmacology and Experimental Therapeutics 317:
598–605.
Gene Regulation by PAR2
PLoS ONE | www.plosone.org 13 November 2010 | Volume 5 | Issue 11 | e1380933. Moffatt JD (2007) Proteinase-activated receptors in the lower urinary tract.
Naunyn Schmiedebergs Arch Pharmacol 375: 1–9.
34. Kelso EB, Ferrell WR, Lockhart JC, Elias-Jones I, Hembrough T, et al. (2007)
Expression and proinflammatory role of proteinase-activated receptor 2 in
Rheumatoid Synovium. Arthritis & Rheumatism 56: 765–771.
35. Tanaka M, Arai H, Liu N, Nogaki F, Nomura K, et al. (2005) Role of
coagulation factor Xa and protease-activated receptor 2 in human mesangial cell
proliferation. Kidney International 67: 2123–2133.
36. Grandaliano G, Pontrelli P, Cerullo G, Monno R, Ranieri E, et al. (2003)
Protease-Activated Receptor-2 expression in IgA Nephropathy: A potential role
in the pathogenesis of Intertitial Fibrosis. Journal of the American Society of
Nephrology 14: 2072–2083.
37. Vesey DA, Hooper JD, Gobe GC, Johnson DW (2007) Potential physiological
and pathophysiological roles for protease-activated receptor-2 in the kidney.
Nephrology 12: 36–43.
38. Kanke T, Ishiwata H, Kabeya M, Saka M, Doli T, et al. (2005) Binding of a
highly potent protease-activated receptor-2 (PAR2) activating peptide, [
3H]2-
furoyl-LIGRL-NH2, to human PAR2. British Journal of Pharmacology 145:
255–263.
39. McGuire JJ, Saifeddine M, Triggle CR, Sun K, Hollenberg MD (2004) 2-furoyl-
LIGRLO-amide: a potent and selective proteinase-activated receptor 2 agonist.
Journal of Pharmacology and Experimental Therapeutics 309: 1124–1131.
40. McLaughlin JN, Mazzoni MR, Cleator JH, Earls L, Perdiogoto AL, et al. (2005)
Thrombin modulates the expression of a set of genes including thrombospondin-
1 in human microvascular endothelial cells. Journal of Biological Chemistry 280:
22172–22180.
41. Yada K, Shibata K, Matsumoto T, Ohta M, Yokoyama S, et al. (2005) Protease-
activated receptor-2 regulates cell proliferation and enhances cyclooxygenase-2
mRNA expression in human pancreatic cancer cells. Journal of Surgical
Oncology 89: 79–85.
42. Ageilan RI, Croce CM (2007) WWOX in biological control and tumorigenesis.
J Cell Physiol 212: 307–310.
43. Ageilan RI, Pekarsky Y, Herrero JJ, Palamarchuk A, Letofsky J, et al. (2004)
Functional association between Wwox tumor suppressor protein and p73, a p53
homolog. Proc Natl Acad Sci U S A 101: 4401–4406.
44. Coates PJ (2006) Regulating p73 isoforms in human tumours. J Pathol 210:
385–389.
45. Giancotti FG (2007) Targeting integrin beta4 for cancer and anti-angiogenic
therapy. Trends in Pharmacological Sciences 28: 506–511.
46. Chokki M, Equchi H, Hamamura I, Mitsuhashi H, Kamimura T (2005) Human
airway trypsin-like protease induces amphiregulin release through a mechanism
involving protease-activated receptor-2-mediated ERK activation and TNF
alpha-converting enzyme activity in airway epithelial cells. FEBS J 272:
6387–6399.
47. Blanchard F, Chipoy C (2005) Histone deacetylase inhibitors: new drugs for the
treatment of inflammatory diseases? Drug Discov Today 10: 197–204.
48. Halili MA, Andrews MA, Sweet MJ, Fairlie DP (2009) Histone deacetylase
inhibitors in inflammatory disease. Curr Topics Med Chem 9: 309–319.
49. Chung CD, Kuo F, Kumer J, Motani AS, Lawrence CE, et al. (2003) CCR8 Is
Not Essential for the Development of Inflammation in a Mouse Model of
Allergic Airway Disease. The Journal of Immunology 170: 581–587.
50. Nishida K, Komiyama T, Miyazawa S, Shen ZN, Furumatsu T, et al. (2004)
Histone deacetylase inhibitor suppression of autoantibody-mediated arthritis in
mice via regulation of p16INK4a and p21(WAF1/Cip1) expression. Arthritis
Rheum 50: 3365–3376.
51. Reilly CM, Mishra N, Miller JM, Joshi D, Ruiz P, et al. (2004) Modulation of
renal disease in MRL/lpr mice by suberoylanilide hydroxamic acid. J Immunol
173: 4171–4178.
52. Choi JH, Oh SW, Kang MS, Kwon HJ, Oh GT, et al. (2005) Trichostatin A
attenuates airway inflammation in mouse asthma model. Clin Exp Allergy 35:
89–96.
53. Camelo S, Iglesias AH, Hwang D, Due B, Ryu H, et al. (2005) Transcriptional
therapy with the histone deacetylase inhibitor trichostatin A ameliorates
experimental autoimmune encephalomyelitis. J Neuroimmunol 164: 10–21.
54. Marwick JA, Ito K, Adcock IM, Kirkham PA (2007) Oxidative stress and steroid
resistance in asthma and COPD: pharmacological manipulation of HDAC-2 as
a therapeutic strategy. Expert Opin Ther Targets 11: 745–755.
55. Aung HT, Schroder K, Himes SR, Brion K, van Zuylen W, et al. (2006) LPS
regulates proinflammatory gene expression in macrophages by altering histone
deacetylase expression. FASEB J 20: 1315–1327.
56. Challen G, Gardiner B, Caruana G, Kostoulias X, Martinez G, et al. (2005)
Temporal and spatial transcriptional programs in murine kidney development.
Physiological Genomics 23: 159–171.
Gene Regulation by PAR2
PLoS ONE | www.plosone.org 14 November 2010 | Volume 5 | Issue 11 | e13809